Y-mAbs Therapeutics, Inc. Forecasted to Post FY2022 Earnings of ($2.78) Per Share (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Rating) – Investment analysts at HC Wainwright upped their FY2022 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a report released on Monday, November 21st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($2.78) per share for the year, up from their prior forecast of ($2.82). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ Q4 2022 earnings at ($0.57) EPS, Q1 2023 earnings at ($0.51) EPS, Q2 2023 earnings at ($0.46) EPS, Q3 2023 earnings at ($0.40) EPS and Q4 2023 earnings at ($0.37) EPS.

Other research analysts have also issued reports about the company. Canaccord Genuity Group reduced their target price on Y-mAbs Therapeutics from $35.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, October 31st. Canaccord Genuity Group dropped their price target on Y-mAbs Therapeutics from $35.00 to $27.00 in a research note on Monday, October 31st. BMO Capital Markets dropped their price target on Y-mAbs Therapeutics from $29.00 to $12.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 1st. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $17.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, October 31st. Finally, Kempen & Co downgraded Y-mAbs Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $15.50.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ:YMAB opened at $4.29 on Wednesday. The business’s 50-day moving average is $10.30 and its 200 day moving average is $13.25. Y-mAbs Therapeutics has a 1 year low of $2.94 and a 1 year high of $20.48. The firm has a market capitalization of $187.34 million, a P/E ratio of -1.40 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMABGet Rating) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.12. The firm had revenue of $12.54 million during the quarter, compared to analyst estimates of $11.69 million. Y-mAbs Therapeutics had a negative return on equity of 92.65% and a negative net margin of 307.75%.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds have recently modified their holdings of YMAB. DekaBank Deutsche Girozentrale boosted its position in Y-mAbs Therapeutics by 9.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 14,400 shares of the company’s stock worth $172,000 after purchasing an additional 1,300 shares in the last quarter. Strs Ohio boosted its position in Y-mAbs Therapeutics by 6.0% during the second quarter. Strs Ohio now owns 26,600 shares of the company’s stock worth $402,000 after purchasing an additional 1,500 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in Y-mAbs Therapeutics by 1.7% during the second quarter. Rice Hall James & Associates LLC now owns 91,898 shares of the company’s stock worth $1,390,000 after purchasing an additional 1,523 shares in the last quarter. Credit Suisse AG raised its holdings in shares of Y-mAbs Therapeutics by 8.6% during the second quarter. Credit Suisse AG now owns 20,924 shares of the company’s stock valued at $317,000 after acquiring an additional 1,659 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Y-mAbs Therapeutics by 15.8% during the third quarter. Price T Rowe Associates Inc. MD now owns 16,708 shares of the company’s stock valued at $241,000 after acquiring an additional 2,285 shares during the last quarter. Hedge funds and other institutional investors own 56.70% of the company’s stock.

About Y-mAbs Therapeutics

(Get Rating)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Featured Stories

Earnings History and Estimates for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.